"Value creation in the evolving pharmaceutical industry: an industry in flux" Drexel University's LeBow College of Business and the Global Interdependence Center: "THE PHARMACEUTICAL INDUSTRY: STRATEGIC INTERDEPENDENCE IN GLOBAL MARKETS.“
Al Altomari Chief Commercial Officer Barrier Therapeutics, Inc.
1979 to 2005: A personal retrospective Significant events impacting overall valuation • Surprises (foreseeable?): – Pharmacovigilance (Why is the FDA preempting the industry?) – Manufacturing issues – Health care compliance & regulatory issues
• Macro issues: – World wide transparency of price – Industry is truly a global business (M&A has accelerated) – Shift in the drug development model • • • • •
Biological (Pharmacological based) Medicinal Chemistry Genomics Biologics Device/Pharmaceutical (example: stents, nanotechnology)
"Value creation in the evolving pharmaceutical
Al Altomari, Barrier Therapeutics, Inc.
PhRMA Companies continue to invest heavily in R&D; the rate of investment abroad is decelerating $30
US Dollars in Billions
$25 $20 $15 $10
R&D (US)
"Value creation in the evolving pharmaceutical
E 03
02
20
20
00
01 20
20
99 19
98 19
97 19
95
96 19
19
94 19
93 19
92 19
90
91 19
19
89 19
88 19
87 19
85
86 19
19
84 19
83 19
82 19
80
81 19
19
19
$0
79
$5
R&D (Abroad) Al Altomari, Barrier Therapeutics, Inc.
Industry productivity continues to lag in the US. New Medicines, Vaccines and Biologics Approved by the FDA 60
User Fee Impact
50 40 30 20 10 0
1994
1995
1996
1997
1998
1999
"Value creation in the evolving pharmaceutical
2000
2001
2002
2003
Al Altomari, Barrier Therapeutics, Inc.
Current landscape is changing: Biotechnology has attracted capital and has made an impact in the market place
JN J
PF I
250
ZE R
Market Cap (4/22/2005) - US $ Billions
200 TE C EN EN G
B
M S
A
M E
100
M G
RC
EN
K
H
150
50 0
"Value creation in the evolving pharmaceutical
Al Altomari, Barrier Therapeutics, Inc.
Going forward: Creating value in the future in an industry in flux? 1.
Competing in a global environment: – – – – –
2.
Mounting pressure on price from payers Investment/ROI in the emerging markets: China, Eastern Europe Complexity registration process IP protection Currency risk
Emerging regulatory trends: – – –
Registration process focus on “safety” Accounting/Auditing: Sarbanes-Oxley Generic Industry: • Biologics • Impact outside of US
"Value creation in the evolving pharmaceutical
Al Altomari, Barrier Therapeutics, Inc.
Going forward: Creating value in the future in an industry in flux? 3.
Role of start-ups, small/emerging and specialty Pharma: – – –
4.
Continued consolidation and rationalization: – – –
5.
Augment “Big Pharma” Source of technology and innovation Models of efficiency
Less “Mega Mergers” Targeted technology acquisitions Increase in spin-offs and divestures of non-strategic assets
More pressure on margins: Sales forces, manufacturing and R&D spending.
"Value creation in the evolving pharmaceutical
Al Altomari, Barrier Therapeutics, Inc.
There is continued opportunity and responsibility for the Pharmaceutical Industry. Percent of Americans NOT Receiving Recommended Care E. A. McGlynn et al., New England Journal of Medicine 2003
60% 50% 40% 30% 20% 10% 0%
Diabetes
Coronary Artery Disease
Heart Attack Patients
"Value creation in the evolving pharmaceutical
Colorectal Cancer
High Blood Pressure
Al Altomari, Barrier Therapeutics, Inc.
“Never discourage anyone...who continually makes progress, no matter how slow.�
Plato Greek author & philosopher in Athens (427 BC - 347 BC)